【产品介绍】：

生物活性：BIBF 1202-13C,d3 is the 13C- and deuterium labeled BIBF 1202. BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[76].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
BIBF 1202-13C,d3 相关抗体:
VEGF Receptor 2 Antibody (YA014)
VEGF Receptor 1 Antibody
VEGFA Antibody
VEGF Receptor2 Antibody
PLGF Antibody (YA1812)
VEGFD Antibody (YA2385)
PGF Antibody (YA1434)
Neuropilin 1 Antibody (YA1831)
VEGFB Antibody (YA2627)
分子量：529.61
Formula：C2913CH28D3N5O4
非标记 CAS：894783-71-2
性状：固体
颜色：Light yellow to yellow
中文名称：尼达尼布杂质6)-13C,d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Powder：-20°C：3 years，4°C：2 years
In solvent：-80°C：6 months，-20°C：1 month
纯度 & 产品资料
纯度： 99.70%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.
 [Content Brief]
[2]. Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumorefficacy. Cancer Res. 2008 Jun 15;68(12):4774-82.
 [Content Brief]
[3]. Stopfer P, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011 Apr;41(4):297-311.
 [Content Brief]